The anti-PD-1 monoclonal antibodies (mAb) Nivolumab and Pembrolizumab block the interaction of tumor-reactive T cells expressing PD-1 with leukocytes and tumor cells expressing PD-L1 and PD-L2 (40). Here, PDCD1 is linked to neoplasm.